Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue

Prostate Cancer and Prostatic Diseases volume 6, pages 217–222 (2003)Cite this article

Abstract

Matrix metalloproteinases (MMPs) have been implicated in progression and metastases of different tumours. The balance between the MMPs and their natural inhibitors (tissue inhibitors of matrix metalloproteinases; TIMP) seems to be an important factor related to this role. Here, the expression of MMP-2 and -9 along with TIMP-1 and -2 was examined in prostate cancer tissue. A total of 40 radical prostatectomy specimens were embedded in paraffin and immunohistochemical staining was performed to detect MMP-2 and -9, and TIMP-1 and -2. The immunoreactivity was assessed semiquantitively using routine light microscopy. The intensity of staining was correlated to preoperative PSA, T category, Gleason score and clinical parameters of the specimens. The imbalance of MMPs and TIMPs was recognised as a significant loss of TIMP-1 in malignant epithelium and an upregulation of MMPs. Palpable tumours (T2, T3) expressed significantly more MMP-2 and significantly less MMP-9 than T1c tumours. Our data are in accordance with other literature reports in that an imbalance of MMPs and TIMPs is found in malignant tumours. The observed imbalance of MMP and TIMP is mainly caused by a loss of TIMP-1. Furthermore, palpable tumours demonstrated significantly more MMP-2 and significantly less MMP-9 expression than nonpalpable tumours.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Liotta LA, Rao CN, Barsky SH . Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636–649.

    CAS  PubMed  Google Scholar 

  2. Wysocki AB, Staiano CL, Grinnell F . Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64–68.

    Article  CAS  PubMed  Google Scholar 

  3. Mikuni TY, Cheng YS . Metalloproteinases in endochondral bone formation: appearance of tissue inhibitor-resistant metalloproteinases. Arch Biochem Biophys 1987; 259: 576–588.

    Article  Google Scholar 

  4. Huppertz B et al. Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. Cell Tissue Res 1998; 291: 133–148.

    Article  CAS  PubMed  Google Scholar 

  5. Murray GI . Matrix metalloproteinases: a multifunctional group of molecules. J Pathol 2001; 195: 135–137.

    Article  CAS  PubMed  Google Scholar 

  6. Ahrens D et al. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996; 39: 1576–1587.

    Article  CAS  PubMed  Google Scholar 

  7. Arthur MJ . Degradation of matrix proteins in liver fibrosis. Pathol Res Pract 1994; 190: 825–833.

    Article  CAS  PubMed  Google Scholar 

  8. Parsons SL et al. Matrix metalloproteinases [see comments]. Br J Surg 1997; 84: 160–166.

    Article  CAS  PubMed  Google Scholar 

  9. Docherty AJ, O'Connell J, Crabbe T, Angal S, Murphy G . The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol 1992; 10: 200–207.

    Article  CAS  PubMed  Google Scholar 

  10. Karakiulakis G et al. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 1997; 17: 158–168.

    CAS  PubMed  Google Scholar 

  11. Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP . Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res 2001; 21: 3821–3828.

    CAS  PubMed  Google Scholar 

  12. Pagenstecher A et al. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001; 60: 598–612.

    Article  CAS  PubMed  Google Scholar 

  13. Wilson MJ et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and –2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol 2002; 191: 208–216.

    Article  CAS  PubMed  Google Scholar 

  14. Varani J et al. Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue. Br J Cancer 2001; 84: 1076–1083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Crawford HC, Matrisian LM . Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 1996; 49: 20–37.

    Article  CAS  PubMed  Google Scholar 

  16. Nagase H . Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151–160.

    CAS  PubMed  Google Scholar 

  17. Bee A et al. Canine TIMP-2: purification, characterization and molecular detection [In Process Citation]. Vet J 2000; 160: 126–134.

    Article  CAS  PubMed  Google Scholar 

  18. Liu YE et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 1997; 272: 20479–20483.

    Article  CAS  PubMed  Google Scholar 

  19. Schaefer L et al. Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. Diabetologia 1997; 40(9): 1035–1043.

    Article  CAS  PubMed  Google Scholar 

  20. Kodate M et al. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 1997; 47: 461–469.

    Article  CAS  PubMed  Google Scholar 

  21. Gallegos NC et al. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol 1995; 4: 111–119.

    Article  CAS  PubMed  Google Scholar 

  22. Polette M et al. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 1993; 13: 31–37.

    CAS  PubMed  Google Scholar 

  23. Boag AH, Young ID . Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 1994; 144: 585–591.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Schmid HP, McNeal JE . An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am J Surg Pathol 1992; 16: 184–191.

    Article  CAS  PubMed  Google Scholar 

  25. Davies B et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365–5369.

    CAS  PubMed  Google Scholar 

  26. Poulsom R et al. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389–396.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Asai M et al. Differential regulation of MMP-9 and TIMP-2 expression in malignant melanoma developed in metallothionein/RET transgenic mice. Jpn J Cancer Res 1999; 90: 86–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Stearns ME, Wang M, Stearns M . IL-10 blocks collagen IV invasion by ‘invasion stimulating factor’ activated PC-3 ML cells: upregulation of TIMP-1 expression. Oncol Res 1995; 7: 157–163.

    CAS  PubMed  Google Scholar 

  29. DeClerck YA et al. Tissue inhibitors of metalloproteinases: role in tumor progression. Contrib Nephrol 1994; 107: 108–115.

    Article  CAS  Google Scholar 

  30. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler SW . Tumor cell invasion inhibited by TIMP-2 [see comments]. J Natl Cancer Inst 1991; 83: 775–779.

    Article  CAS  PubMed  Google Scholar 

  31. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR . Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182: 347–355.

    Article  CAS  PubMed  Google Scholar 

  32. Kinoshita T et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998; 273: 16098–16103.

    Article  CAS  PubMed  Google Scholar 

  33. Caterina JJ et al. Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2(Timp-2) gene alters proMMP-2 activation. J Biol Chem 2000; 275: 26416–26422.

    Article  CAS  PubMed  Google Scholar 

  34. Sakata K, Shigemasa K, Nagai N, Ohama K . Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary [In Process Citation]. Int J Oncol 2000; 17: 673–681.

    CAS  PubMed  Google Scholar 

  35. Cooner WH et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146–1152.

    Article  CAS  PubMed  Google Scholar 

  36. Geary ES, Stamey TA . Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4–10 ng/ml [see comments]. J Urol 1996; 156: 1056–1058.

    Article  CAS  PubMed  Google Scholar 

  37. Epstein JI, Walsh PC, Brendler CB . Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C) [see comments]. J Urol 1994; 152: 1721–1729.

    Article  CAS  PubMed  Google Scholar 

  38. Agren MS et al. Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans. Br J Surg 1998; 85: 68–71.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic of Urology, University Clinic Aachen, Germany

    B Brehmer & G Jakse

  2. Institute of Pathology, University Clinic Aachen, Germany

    S Biesterfeld

Authors
  1. B Brehmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Biesterfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Jakse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Brehmer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brehmer, B., Biesterfeld, S. & Jakse, G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 6, 217–222 (2003). https://doi.org/10.1038/sj.pcan.4500657

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500657

Keywords

This article is cited by

Search

Advanced search

Quick links